ENTRY       D00749                      Drug
NAME        Leflunomide (JAN/USP/INN);
            Arava (TN)
PRODUCT     ARAVA (sanofi-aventis U.S. LLC)
  GENERIC   LEFLUNOMIDE (A-S Medication Solutions)
            LEFLUNOMIDE (Alembic Pharmaceuticals Limited)
            LEFLUNOMIDE (Alembic Pharmaceuticals)
            LEFLUNOMIDE (Apotex Corp.)
            LEFLUNOMIDE (Aurobindo Pharma Limited)
            LEFLUNOMIDE (AvKARE)
            LEFLUNOMIDE (AvPAK)
            LEFLUNOMIDE (Bryant Ranch Prepack)
            LEFLUNOMIDE (Bryant Ranch Prepack)
            LEFLUNOMIDE (Burel Pharmaceuticals)
            LEFLUNOMIDE (Fosun Pharma USA)
            LEFLUNOMIDE (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals)
            LEFLUNOMIDE (KVK-Tech)
            LEFLUNOMIDE (Lupin Pharmaceuticals)
            LEFLUNOMIDE (REMEDYREPACK)
            LEFLUNOMIDE (Winthrop U.S.)
            LEFLUNOMIDE (Zydus Lifesciences Limited)
            LEFLUNOMIDE (Zydus Pharmaceuticals (USA))
FORMULA     C12H9F3N2O2
EXACT_MASS  270.0616
MOL_WEIGHT  270.2073
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG01643  CYP2C9 inhibitor
REMARK      Same as: C07905
            Therapeutic category: 3999
            ATC code: L04AA13
            Product: D00749<JP/US>
EFFICACY    Antirheumatic, Dihydroorotate dehydrogenase inhibitor
  DISEASE   Active rheumatoid arthritis [DS:H00630]
COMMENT     Antineoplastic (blocks PDGF receptor function, inhibiting the growth and survival of human tumor cells when administered intravenously), Used in the treatment of rheumatoid arthritis when administered orally
TARGET      DHODH [HSA:1723] [KO:K00254]
  PATHWAY   hsa00240(1723)  Pyrimidine metabolism
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION CYP inhibition: CYP2C9 [HSA:1559]
STR_MAP     map07046  Immunosuppressive agents
            map07050  Antirheumatics - DMARDs and biological agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA13 Leflunomide
                  D00749  Leflunomide (JAN/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunosuppressants
               Antimetabolites, Antiproliferative
                Leflunomide
                 D00749  Leflunomide (JAN/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D00749  Leflunomide (JAN/USP/INN)
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D00749  Leflunomide
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D00749  Leflunomide
             Metabolizing enzyme inhibitor
              DG01643  CYP2C9 inhibitor
               D00749  Leflunomide
            Drug classes [BR:br08332]
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D00749  Leflunomide
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Oxidoreductases (EC1)
               Dehydrogenases
                DHODH
                 D00749  Leflunomide (JAN/USP/INN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D00749
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D00749
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00749
DBLINKS     CAS: 75706-12-6
            PubChem: 7847814
            ChEBI: 6402
            LigandBox: D00749
            NIKKAJI: J227.599F
ATOM        19
            1   C8y C    22.4985  -19.9460
            2   C5a C    23.7261  -19.2621
            3   C8y C    22.4985  -21.3488
            4   C8x C    21.1659  -19.5077
            5   N1b N    24.9360  -19.9577
            6   O5a O    23.7261  -17.8652
            7   O2x O    21.1601  -21.7813
            8   C1a C    23.6268  -22.1788
            9   N5x N    20.3360  -20.6415
            10  C8y C    26.1460  -19.2621
            11  C8x C    26.1460  -17.8592
            12  C8x C    27.3617  -19.9577
            13  C8x C    27.3617  -17.1637
            14  C8x C    28.5657  -19.2621
            15  C8y C    28.5657  -17.8592
            16  C1d C    29.7756  -17.1580
            17  X   F    30.9798  -16.4506
            18  X   F    29.0684  -15.9421
            19  X   F    30.4653  -18.3677
BOND        20
            1     1   2 1
            2     1   3 2
            3     1   4 1
            4     2   5 1
            5     2   6 2
            6     3   7 1
            7     3   8 1
            8     4   9 2
            9     5  10 1
            10   10  11 2
            11   10  12 1
            12   11  13 1
            13   12  14 2
            14   13  15 2
            15   15  16 1
            16   16  17 1
            17   16  18 1
            18   16  19 1
            19    7   9 1
            20   14  15 1
///
